Overview of trends in the control of cardiac arrhythmia: past and future

Singh, Bramah N.

doi:10.1016/s0002-9149(99)00696-7

Cited by 13 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The electrophysiologic effects of the drug differ markedly depending on whether it is given short-term or after a long-term period of drug therapy, both of which are associated with distinct and potent antiarrhythmic actions. The electropharmacologic effects of the compound are multifaceted (29,49), and the most striking long-term effect of amiodarone is increased action potential duration in the atrial muscle, which may exceed that in the ventricular muscle (8,49).…”

Section: β-Blocking Drugs As Atrial Antifibrillatory Agents: the Futumentioning

confidence: 99%

“…In the past 15 years, clinical trials (both controlled and uncontrolled, blinded and unblinded) have shown that amiodarone is the most potent antiarrhythmic drug for maintaining sinus rhythm in patients with AF (49,50). However, even with such a potent agent as amiodarone, AF recurs in 40% of patients (50).…”

Section: β-Blocking Drugs As Atrial Antifibrillatory Agents: the Futumentioning

confidence: 99%

See 1 more Smart Citation

β-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview

Singh

2005

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Beta-Adrenergic blockers have a wide spectrum of action for controlling cardiac arrhythmias that is larger than initially thought. Data from the past several decades indicate that, as an antiarrhythmic class, beta-blockers remain among the very few pharmacologic agents that reduce the incidence of sudden cardiac death, prolong survival, and ameliorate symptoms caused by arrhythmias in patients with cardiac disease. As a class of compounds, beta-blockers have a fundamental pharmacologic property that attenuates the effects of competitive adrenergic receptors. However, the net clinical effects of the different beta-receptor blockers may vary quantitatively because of variations in associated intrinsic sympathomimetic agonism and in their intrinsic potency for binding to beta-receptors. These individual compounds also differ in their selectivity for beta(1)- and beta(2)-receptors. Metoprolol is a beta(1)-selective blocker, whereas carvedilol is a nonselective beta(1)- and beta(2)-blocker, an antioxidant, and has a propensity to inhibit alpha(1)-receptors and endothelin. Evolving data from controlled and uncontrolled clinical trials suggest that there are clinically significant differences among this class of drugs. Recent evidence also suggests that the antiarrhythmic actions of certain beta-receptor blockers such as carvedilol and metoprolol extend beyond the ventricular tissue to encompass atrial cells and help maintain sinus rhythm in patients with atrial fibrillation, especially in combination with potent antifibrillatory agents such as amiodarone. This introduction provides a current perspective on these newer developments in the understanding of the antiarrhythmic and antifibrillatory actions of beta-blockers.

show abstract

Section: β-Blocking Drugs As Atrial Antifibrillatory Agents: the Futumentioning

confidence: 99%

Section: β-Blocking Drugs As Atrial Antifibrillatory Agents: the Futumentioning

confidence: 99%

β-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview

Singh

2005

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The intraventricular cardioverter defibrillator (ICD) was first used clinically in the early 1980s (Morris et al, 1999). Controlled clinical trials have since demonstrated the value of ICDs in reducing sudden cardiac death in patients with ventricular arrhythmias (Singh, 1999). For patients with ventricular fibrillation or hemodynamically intolerable sustained ventricular tachycardia, the use of ICDs has been the standard of care for at least five years.…”

Section: Panel Meetingmentioning

confidence: 99%

Health Status and Medical Treatment of the Future Elderly: Final Report

Goldman¹

2004

View full text Add to dashboard Cite

show abstract

“…Cardiac arrhythmia (CA) is a very common disorder for patients with cardiovascular disease, which is often characterized as any change from the normal sequence of electrical impulses. [1–3] Many factors are account for this disorder, such as smoking, high blood pressure, diabetes, high cholesterol, obesity, a high-fat diet, drug abuse, stress, family history, and so on. [4–10] It has been reported that about 2% to 3% of the population in Europe and North America experienced such condition in 2014.…”

Section: Introductionmentioning

confidence: 99%

Amiodarone and acupuncture for cardiac arrhythmia

Meng

Gao²,

Sun³

2019

Medicine

View full text Add to dashboard Cite

Background: Amiodarone and acupuncture (AA) are commonly used to treat cardiac arrhythmia (CA). The objective of this systematic review is to assess the efficacy and safety of AA for patients with CA. Methods: Randomized controlled trials (RCTs) of AA for CC will be searched from 9 databases including PubMed, EMBASE, Cochrane Library, Web of Science, Scopus, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data from inception to February 1, 2019 without any limitations. Two reviewers will independently screen the relevant papers, extract data, and evaluate the risk of bias for each included study. RevMan 5.3 software will be used for meta-analysis. The primary outcome includes arrhythmic episodes (including time and frequency domain parameters). The secondary outcomes consist of health-related quality of life, oxygen saturation, and safety. Results: The protocol of this proposed study will provide evidence to judge whether AA is an effective treatment for patients with CA. Conclusion: The findings of this proposed study will summarize the up-to-date evidence of AA for CA. PROSPERO registration number: PROSPERO CRD42019120962.

show abstract

Overview of trends in the control of cardiac arrhythmia: past and future

Cited by 13 publications

References 41 publications

β-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview

β-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview

Health Status and Medical Treatment of the Future Elderly: Final Report

Amiodarone and acupuncture for cardiac arrhythmia

Contact Info

Product

Resources

About